EKOS(R) Introduces New EkoSonic(TM) Endovascular System With Rapid Pulse(TM) Modulation...

EKOS(R) Introduces New EkoSonic(TM) Endovascular System With Rapid Pulse(TM) Modulation Technology - Four Times Faster Than Conventional Catheter-Directed Thrombolysis

With No Evidence of Thrombus Breakage or Hemolysis
BOTHELL, Wash.--(Business Wire)--
EKOS Corporation announced today the launch of the EkoSonic(TM)
Endovascular System (EkoSonic ES) with Rapid Pulse Modulation (RPM)
for the dissolution of vascular blood clots. EkoSonic ES is the only
endovascular system that can deliver microsonic energy and
thrombolytic drugs simultaneously, providing a safer, faster and more
complete way to remove clots by accelerating dissolution. The EkoSonic
ES recently received FDA clearance.

Shortening Lysis Time With RPM, The Innovative Safe Technology

Intermittent bursts of microsonic energy effectively increase the
permeability of the clot to the thrombolytic - 4 times faster than
conventional catheter-directed thrombolysis with no evidence of
thrombus breakage or hemolysis.

"Unlike mechanical devices, EKOS technology does not fracture the
thrombus or damage red blood cells. Faster clot dissolution means a
lower lytic drug dosage, resulting in fewer complications. Physicians
can treat patients in less time, with even greater clinical
confidence," said Robert Hubert, EKOS president and CEO.

User-Friendly Design Features

In addition to its unique RPM technology, EkoSonic ES design
features include an advanced control unit with an easier, more
intuitive user interface, making set up and operation simple. EkoSonic
ES is also compatible with a new line of endovascular devices,
EkoSonic(TM) Mach 4 Endovascular Device, (Mach 4). The Mach 4 was
specifically created to be compatible with the RPM technology.

The Mach 4 offers a variety of treatment zone options. Each Mach 4
consists of a MicroSonic(TM) Core within an Intelligent(TM) Drug
Delivery Catheter. This combination device enables the system to
deliver microsonic energy and drugs simultaneously to accelerate clot
dissolution. Reduction in time translates to fewer drugs, lowering the
risk profile of the procedure while the convergence of technologies
results in a safer, faster, more complete outcome in the treatment of
Deep Vein Thrombosis (DVT) and Peripheral Arterial Occlusions (PAO).

Over the past three years, physicians have responded favorably
after performing nearly 6,000 cases utilizing the EKOS technology. "We
predict that the EkoSonic will become the new gold standard to treat
patients with vascular thrombosis," concluded Hubert.

Major U.S. medical centers utilizing the EkoSonic ES include
Baptist Cardiac & Vascular Institute (Miami, FL), Cleveland Clinic
Foundation (Cleveland, OH), Dartmouth-Hitchcock Medical Center
(Lebanon, NH), Emory University Hospital (Atlanta, GA), Massachusetts
General Hospital (Boston, MA), The Methodist Hospital (Houston, TX),
University of Illinois Medical Center at Chicago (Chicago, IL), and
the Swedish Medical Center (Seattle, WA).

About Deep Venous Thrombosis

The Vascular Disease Foundation (VDF) states that DVT occurs when
a blood clot, or thrombus, develops in the large veins of the legs or
pelvic area. Some DVT's may cause no pain, whereas others can be quite
painful. With prompt diagnosis and treatment, the majority of DVT's
are not life threatening. However, a blood clot that forms in the
invisible "deep veins" can be an immediate threat to your life, as
compared to a clot that forms in the visible "superficial" veins, the
ones beneath your skin. A clot that forms in the large, deep veins is
more likely to break free and travel through the vein. It is then
called an embolus. When an embolus travels from the legs or pelvic
areas and lodges in a lung artery, the condition is known as a
"pulmonary embolism," or PE, a potentially fatal condition if not
immediately diagnosed and treated.

About Peripheral Arterial Occlusion (PAO) Disease

The arteries are the vessels in the body that supply oxygenated
blood to the tissues. Acute peripheral arterial occlusion results in
the sudden cessation of blood flow to an extremity of the body. The
main cause of a sudden blockage of arteries leading to the extremities
(peripheral arteries) is due to the local accumulation of cells
(thrombus) and material within the artery or because a clot has been
brought to a site by the blood stream (embolism). A common site for
PAO disease is in the extremities.

Typically, the affected limb shows pallor, feels cold and becomes
painful. The local nerves may become severely damaged, leading to
paralysis (inability to move the limb). The lack of oxygen in the limb
due to the obstruction of the artery can lead to gangrene (a loss of
viable tissue). Restoring oxygen to the effected tissues requires fast
and quick treatment of the affected artery. Reperfusion is important
to minimize debilitating and potentially life-threatening negative
outcomes.

About EKOS Corporation

EKOS Corporation pioneered the development and clinical
application of microsonic technologies in medicine, introducing its
first system for the treatment of vascular thrombosis in 2005. Today,
interventional radiologists, cardiologists and vascular surgeons at
leading institutions across the nation use EKOS MicroSonic(TM)
Accelerated Thrombolysis (MSAT) to provide faster, safer and more
complete dissolution of thrombus. In 2008, the company introduced 2nd
generation EkoSonic(TM) Endovascular System with Rapid Pulse(TM)
Modulation. The EkoSonic System is FDA-cleared for controlled and
selective infusion of physician-specified fluids, including
thrombolytic, into the peripheral vasculature. It is currently used to
treat patients with peripheral arterial occlusions (PAO) and deep vein
thrombosis (DVT) and additional applications are being investigated.
Visit www.ekoscorp.com

PTM Healthcare Marketing, Inc.
Pauline T. Mayer, 631-979-3780
PTM@ptmhcm.com

Copyright Business Wire 2008